Abstract
Ibuprofen is one of the most popular NSAIDs for the last three decades but also known for its gastrointestinal side effects similar to other NSAIDs. To overcome this problem, we have designed and synthesized ibuprofen - antioxidant (thymol, guaiacol, eugenol, and menthol) hybrids (6-13) with and without spacer as gastro sparing agents. The hybrids have been found to be chemically stable, biolabile and exhibited retention of anti-inflammatory and analgesic activity with significant reduced ulcerogenicity as compared to the ibuprofen and ibuprofen + antioxidant physical mixture. The absence of ulcerogenicity may be attributed to antioxidants and improved physicochemical properties of these hybrid molecules.
Keywords: Ibuprofen, Antioxidants, Ulcerogenicity, Chemical stability.
Medicinal Chemistry
Title:Synthesis and Evaluation of Antioxidant-S-(+)-Ibuprofen Hybrids as Gastro Sparing NSAIDs
Volume: 9 Issue: 7
Author(s): Senthil Chandiran, Sandeep Vyas, Neetika Sharma and Manu Sharma
Affiliation:
Keywords: Ibuprofen, Antioxidants, Ulcerogenicity, Chemical stability.
Abstract: Ibuprofen is one of the most popular NSAIDs for the last three decades but also known for its gastrointestinal side effects similar to other NSAIDs. To overcome this problem, we have designed and synthesized ibuprofen - antioxidant (thymol, guaiacol, eugenol, and menthol) hybrids (6-13) with and without spacer as gastro sparing agents. The hybrids have been found to be chemically stable, biolabile and exhibited retention of anti-inflammatory and analgesic activity with significant reduced ulcerogenicity as compared to the ibuprofen and ibuprofen + antioxidant physical mixture. The absence of ulcerogenicity may be attributed to antioxidants and improved physicochemical properties of these hybrid molecules.
Export Options
About this article
Cite this article as:
Chandiran Senthil, Vyas Sandeep, Sharma Neetika and Sharma Manu, Synthesis and Evaluation of Antioxidant-S-(+)-Ibuprofen Hybrids as Gastro Sparing NSAIDs, Medicinal Chemistry 2013; 9 (7) . https://dx.doi.org/10.2174/1573406411309070015
DOI https://dx.doi.org/10.2174/1573406411309070015 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mimicking Microvascular Alterations of Human Diabetic Retinopathy: A Challenge for the Mouse Models
Current Medicinal Chemistry The Genetic Basis of New Treatment Modalities in Melanoma
Current Drug Targets Recent Advances in Hematopoietic Stem Cell-Mediated Regeneration
Recent Patents on Regenerative Medicine Non-Steroidal Anti-Inflammatory Drugs as Anti-Amyloidogenic Compounds
Current Pharmaceutical Design A Diabetes Treatment Strategy to Reduce the Risk of Cardiovascular Events: Clinical Benefits and Potential of Linagliptin
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Thiazolidinediones and Cardiovascular Risk — A Question of Balance
Current Cardiology Reviews Chondroitin Sulphate for the Treatment of Osteoarthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets <i>Ajuga</i> L.: A Systematic Review on Chemical Composition, Phytopharmacological and Biological Potential
Current Bioactive Compounds Efficacy of PD-1 or PD-L1 Inhibitors and Central Nervous System Metastases in Advanced Cancer: A Meta-Analysis
Current Cancer Drug Targets Medical Complications in Anorexia and Bulimia Nervosa
Endocrine, Metabolic & Immune Disorders - Drug Targets Delivery Systems of Opioid Analgesics for Pain Relief: A Review
Current Pharmaceutical Design Mesenchymal Stem Cells for Ischemic Stroke: Progress and Possibilities
Current Medicinal Chemistry New Molecular Targets in the Treatment of NSCLC
Current Pharmaceutical Design Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design Synthetic and Natural Coumarins as Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Targeted Radiotherapy for Malignant Gliomas
Current Drug Discovery Technologies Prospective for Diagnosis and Treatment of Diabetic Retinopathy
Current Pharmaceutical Design Development of COX-2 Selective Inhibitors - Therapeutic Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience